At Alcon, our pharmaceutical products, such as ROCKLATAN® (netarsudil 0.02%/latanoprost 0.005% ophthalmic solution), are designed, manufactured and marketed with a body of science developed through rigorous bench research and clinical studies. As the body of knowledge behind Alcon’s products grows, so does the challenge of making our customers aware of its depth. Our medical affairs organization is thus focused on both high-quality data generation and its communication to the clinical community. High-quality scientific publications are essential to convey the clinical community’s knowledge and experience with the latest technology. This clinical science compendium provides a consolidated view of peer-reviewed publications for ROCKLATAN® (netarsudil 0.02%/latanoprost 0.005% ophthalmic solution), a fixed- dose combination of a Rho kinase inhibitor and prostaglandin F2α analog for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.